Epclusa 200 mg/1
Velpatasvir and Sofosbuvir · TABLET, FILM COATED · Gilead Sciences, Inc.
Epclusa is an oral tablet used to treat hepatitis C virus infection and contains two antiviral medications that work together to stop the virus from replicating. It is a prescription medication that combines a nucleotide analog polymerase inhibitor with another antiviral agent to help cure hepatitis C in many patients.
Key Facts
- Brand Name
- Epclusa
- Generic Name
- Velpatasvir and Sofosbuvir
- NDC Code (Product)
61958-2203- Manufacturer
- Gilead Sciences, Inc.
- Strength
- 200 mg/1
- Dosage Form
- TABLET, FILM COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA208341
- Drug Class
- Hepatitis C Virus NS5A Inhibitor [EPC]; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
- Marketing Start
- 03/19/2020
Recall History
No Recall HistoryFrequently Asked Questions
What is Epclusa used for?
Epclusa is an oral tablet used to treat hepatitis C virus infection and contains two antiviral medications that work together to stop the virus from replicating. It is a prescription medication that combines a nucleotide analog polymerase inhibitor with another antiviral agent to help cure hepatitis C in many patients.
Is Epclusa a controlled substance?
Epclusa is not classified as a controlled substance by the DEA.
What is the generic name for Epclusa?
The generic name for Epclusa is Velpatasvir and Sofosbuvir. There are 1 other brand versions of Velpatasvir and Sofosbuvir.
What is the NDC code for Epclusa 200 mg/1?
The NDC (National Drug Code) for Epclusa 200 mg/1 is 61958-2203, listed by Gilead Sciences, Inc..